![]() |
|
|
|
|
|
|
|
|
|
|
Indication: ALPHAGAN® P 0.1% ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Important Safety Information Contraindication: ALPHAGAN® P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Precautions: Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Adverse reactions: Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse events occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. Please click here for full product information. 1. MedlinePlus® Medical Encyclopedia. US National Library of Medicine and the National Institutes of Health Web site. http://www.nlm.nih.gov/medlineplus/encyclopedia.html. Accessed July 2, 2009. 2. MedlinePlus® Medical Dictionary. US National Library of Medicine and the National Institutes of Health Web site. http://www.nlm.nih.gov/medlineplus/mplusdictionary.html. Accessed July 2, 2009. 3. Glaucoma Research Foundation. Glaucoma surgery. Glaucoma Research Foundation Web site. http://www.glaucoma.org/treating/surgery.html. Accessed July 6, 2009. 4. American Optometric Association. Ocular hypertension. American Optometric Association Web site. http://aoa.org/ocular-hypertension.xml. Accessed July 6, 2009. 5. National Eye Institute. Facts about glaucoma. National Eye Institute Web site. http://www.nei.nih.gov/health/glaucoma/glaucoma_facts.asp. Accessed July 2, 2009. |
|
|


